Home
|
Learning Center
|
中文版
Publications
站内成果搜索:
搜索
App应用程序交互设计与平面设计基础研究
App杂志运营模式浅析
App杂志受众的“使用与满足”研究
App在档案服务中的利用
Apr3 accelerates the senescence of human retinal pigment epithelial cells
aprABC: a Mycobacterium tuberculosis complex-specific locus that modulates pH-driven adaptation to the macrophage phagosome
aprK基因敲除的氨甲酰妥布霉素工程菌的构建
Apraxia Impairs Intentional Retrieval of Incidentally Acquired Motor Knowledge
Apraxia related with subcortical lesions due to cerebrovascular disease
Aprataxin, poly-ADP ribose polymerase 1 (PARP-1) and apurinic endonuclease 1 (APE1) function together to protect the genome against oxidative damage
Apraxia and Alzheimer%26apos;s Disease: Review and Perspectives
Apraxia - Agreements and controversies
Apratoxin H and Apratoxin A Sulfoxide from the Red Sea Cyanobacterium Moorea producens
Apraxia of speech in healthy 36-year-old man
Apraxia and Motor Dysfunction in Corticobasal Syndrome
Apraxia in Mild Cognitive Impairment and Alzheimer's Disease: Validity and Reliability of the Van Heugten Test for Apraxia
Apraxia for differentiating Alzheimer's disease from subcortical vascular dementia and mild cognitive impairment
Apraxia in left-handers
Apraxia of tool use: More evidence for the technical reasoning hypothesis
Apramycin treatment affects selection and spread of a multidrug-resistant Escherichia coli strain able to colonize the human gut in the intestinal microbiota of pigs
Apraxia, Autism, Attention-Deficit Hyperactivity Disorder: Do We Have a New Spectrum?
Apraxia: a gestural or a cognitive disorder?
Apraxia in Parkinson's disease and multiple system atrophy
Apraxia in progressive nonfluent aphasia
Apraxia of lid opening due to a small lesion in basal ganglia: two case reports
Apraxia contributes to the motor deficit in Parkinson's Disease and Multiple System Atrophy
Aprataxin Tumor Levels Predict Response of Colorectal Cancer Patients to Irinotecan-based Treatment
Apraxia of Speech: Perceptual Analysis of Bisyllabic Word Productions Across Repeated Sampling Occasions
Apratoxin Kills Cells by Direct Blockade of the Sec61 Protein Translocation Channel
Apraxia - The cognitive side of motor control
Apraxia of tool use is not a matter of affordances
Apraxia of Speech and Phonological Errors in the Diagnosis of Nonfluent/Agrammatic and Logopenic Variants of Primary Progressive Aphasia
Apraxic agraphia following bithalamic damage
Apraxia of Speech: Concepts and Controversies
Apraxia of speech from a right frontal lesion
Apralactone A and a New Stereochemical Class of Curvularins from the Marine Fungus Curvularia sp.
Apraxia in movement disorders
Aprataxin, a novel protein that protects against genotoxic stress
Aprataxin resolves adenylated RNA-DNA junctions to maintain genome integrity
Aprataxin localizes to mitochondria and preserves mitochondrial function
Apratoxin E, a cytotoxic peptolide from a guamanian collection of the marine cyanobacterium Lyngbya bouillonii
Apraxia, pantomime and the parietal cortex
Apraclonidine in the treatment of ptosis
Apraxia, Autism, Attention-Deficit Hyperactivity Disorder: Do We Have a New Spectrum?
Apraxia in Anti-Glutamic Acid Decarboxylase-Associated Stiff Person Syndrome: Link to Corticobasal Degeneration?
Apraxia: Review and Update
Apraxia of Speech: Perceptual Analysis of Trisyllabic Word Productions Across Repeated Sampling Occasions
Apratoxin S10, a Dual Inhibitor of Angiogenesis and Cancer Cell Growth To Treat Highly Vascularized Tumors
Apratoxin A Shows Novel Pancreas-Targeting Activity through the Binding of Sec 61
Apraxia of eyelid closure in autopsy-confirmed vascular progressive supranuclear palsy
Apraclonidine and my pupil
Apraxic agraphia following thalamic damage: Three new cases
Apraxia of object-related action does not depend on visual feedback
Apratyramide, a Marine-Derived Peptidic Stimulator of VEGF-A and Other Growth Factors with Potential Application in Wound Healing
Apraxia of gait- or apraxia of postural transitions?
Aprepitant's Prophylactic Efficacy in Decreasing Postoperative Nausea and Vomiting in Morbidly Obese Patients Undergoing Bariatric Surgery
Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study
Aprepitant, Granisetron, and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting After High-Dose Melphalan in Autologous Transplantation for Multiple Myeloma: Results of a Randomized, Placebo-Controlled Phase III Trial
Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin
Aprepitant does not alter prednisolone pharmacokinetics in patients treated with R-CHOP
Aprepitant Versus Dexamethasone to Prevent Delayed Emesis After Chemotherapy
Aprepitant Versus Dexamethasone for Preventing Chemotherapy-Induced Delayed Emesis in Patients With Breast Cancer: A Randomized Double-Blind Study
Aprepitant for antiemesis after laparoscopic gynaecological surgery A randomised controlled trial
Aprepitant for postoperative nausea and vomiting: a systematic review and meta-analysis
Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
Apremilast for Behcet's Syndrome - A Phase 2, Placebo-Controlled Study
Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors
Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and Safety
Aprepitant for paediatric chemotherapy-induced nausea and vomiting Reply
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial
Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis
Aprela, a single tablet formulation of bazedoxifene and conjugated equine estrogens (Premarin) for the potential treatment of menopausal symptoms
Aprepitant vs. Multimodal Prophylaxis in the Prevention of Nausea and Vomiting following Extended-Release Epidural Morphine
Aprepitant Use in Children, Adolescents, and Young Adults for the Control of Chemotherapy-Induced Nausea and Vomiting (CINV)
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
Apremilast for the Treatment of Moderate to Severe Plaque Psoriasis: A Critique of the Evidence
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
Aprepitant, a NK1 receptor antagonist, improves both airway inflammation and depressive-like behaviors in a rat model with asthma and depression
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity
Apremilast: First Global Approval